Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.65 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.65 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.65 |
| ▸ | MAPK10 | P53779 | 12/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477632 | 0.87 | MAPK8 (0.68) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL6484491 | 0.86 | MAPK8 (0.68) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL6477066 | 0.85 | MAPK8 (0.67) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL6484326 | 0.83 | EGFR (0.64) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| Diethylamine SCHEMBL6478017 | 0.82 | EGFR (0.68) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL6476578 | 0.81 | MAPK8 (0.71) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL6489073 | 0.81 | MAPK8 (0.71) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL6483479 | 0.79 | MAPK8 (0.68) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL6477504 | 0.79 | MAPK8 (0.68) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL6485328 | 0.79 | EGFR (1.00) | EGFRMAPK8MAPK9MAPK10HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6891039-B2 | Imidazo [4,5-B] pyridine compounds and their pharmaceuticals use | NOVARTIS AG (CH) | 2005-05-10 | — | — | US | disclosed |
| US-6608072-B1 | Inhibiting production of soluble tumor necrosis factor or reducing inflammation | NOVARTIS AG (CH) | 2003-08-19 | — | — | US | disclosed |